{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:02:33Z","timestamp":1790740953363,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["Project 101097094 \\u2014 ELMUMY"],"award-info":[{"award-number":["Project 101097094 \\u2014 ELMUMY"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["PLBIO22 PIC-ASO (INCA_16734)"],"award-info":[{"award-number":["PLBIO22 PIC-ASO (INCA_16734)"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["PGA EpiMM3D"],"award-info":[{"award-number":["PGA EpiMM3D"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016913","name":"MSDAVENIR","doi-asserted-by":"publisher","award":["EpiMuM-3D"],"award-info":[{"award-number":["EpiMuM-3D"]}],"id":[{"id":"10.13039\/100016913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004795","name":"Institut Universitaire de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-CE15-0016-01 EPI-B-PLASMADIFF"],"award-info":[{"award-number":["ANR-23-CE15-0016-01 EPI-B-PLASMADIFF"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021568","name":"Office Fran\u00e7ais de la Biodiversit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tranon.2026.103000","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:39:20Z","timestamp":1787953160000},"page":"103000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling"],"prefix":"10.1016","volume":"72","author":[{"given":"Ang\u00e9lique","family":"Bruyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9453-156X","authenticated-orcid":false,"given":"Jules","family":"Varbedian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Garcia De Paco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauryn","family":"Jaffory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Boireau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-2366","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Vialaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Martineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5573-6945","authenticated-orcid":false,"given":"Bruno","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Requirand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5904-1286","authenticated-orcid":false,"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5717-3207","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Moreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4784-2566","authenticated-orcid":false,"given":"Caroline","family":"Bret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.103000_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1471-4906(02)02223-8","article-title":"CD200 and membrane protein interactions in the control of myeloid cells","volume":"23","author":"Barclay","year":"2002","journal-title":"Trends. Immunol."},{"key":"10.1016\/j.tranon.2026.103000_bib0002","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.3390\/biomedicines11123326","article-title":"CD200\/CD200R: bidirectional role in cancer progression and immunotherapy","volume":"11","author":"Nip","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.tranon.2026.103000_bib0003","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbrc.2007.11.103","article-title":"CD200: a putative therapeutic target in cancer","volume":"366","author":"Moreaux","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tranon.2026.103000_bib0004","first-page":"3922","article-title":"CD200 is induced by ERK and is a potential therapeutic target in melanoma","volume":"117","author":"Petermann","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tranon.2026.103000_bib0005","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/ajcp\/aqx071","article-title":"CD200 Expression in neuroendocrine neoplasms","volume":"148","author":"Love","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.tranon.2026.103000_bib0006","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/eji.200425080","article-title":"The CD200 and CD200 receptor cell surface proteins interact through their N-terminal immunoglobulin-like domains","volume":"34","author":"Hatherley","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tranon.2026.103000_bib0007","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000252803","article-title":"Expression of the inhibitory CD200 receptor is associated with alternative macrophage activation","volume":"2","author":"Koning","year":"2010","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.tranon.2026.103000_bib0008","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4049\/jimmunol.176.1.191","article-title":"Regulation of myeloid cell function through the CD200 receptor","volume":"176","author":"Jenmalm","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2026.103000_bib0009","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.4049\/jimmunol.171.6.3034","article-title":"Characterization of the CD200 receptor family in mice and humans and their interactions with CD200","volume":"171","author":"Wright","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2026.103000_bib0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-030-35582-1_8","article-title":"CD200-CD200R Pathway in the regulation of tumor immune microenvironment and immunotherapy","volume":"1223","author":"Liu","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.tranon.2026.103000_bib0011","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma","volume":"108","author":"Moreaux","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.103000_bib0012","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2141.2010.08555.x","article-title":"CD200 expression in plasma cell myeloma","volume":"153","author":"Olteanu","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2026.103000_bib0013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1309\/AJCP59UORCYZEVQO","article-title":"Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma","volume":"137","author":"Alapat","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.tranon.2026.103000_bib0014","unstructured":"Pochard, C., Herbaux, C., Gabellier, L., Fornero, L., Robert, N., Requirand, G., et al. Integrative Approach to Find Predictive Markers of Response to Daratumumab in Multiple Myeloma. European Hematology Association (EHA). 2021;Library."},{"key":"10.1016\/j.tranon.2026.103000_bib0015","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.leukres.2013.08.006","article-title":"CD200 expression in patients with Multiple Myeloma: another piece of the puzzle","volume":"37","author":"Conticello","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.tranon.2026.103000_bib0016","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hon.2206","article-title":"Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma","volume":"35","author":"Aref","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.tranon.2026.103000_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106904","article-title":"CD200R signaling contributes to unfavorable tumor microenvironment through regulating production of chemokines by tumor-associated myeloid cells","volume":"26","author":"Lin","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.tranon.2026.103000_bib0018","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150750","article-title":"CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis","volume":"132","author":"Morgan","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tranon.2026.103000_bib0019","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood.2022018658","article-title":"Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy","volume":"143","author":"Tang","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.103000_bib0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.leukres.2018.04.007","article-title":"Cell membrane-bound CD200 signals both via an extracellular domain and following nuclear translocation of a cytoplasmic fragment","volume":"69","author":"Chen","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.tranon.2026.103000_bib0021","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/1097-0142(19920315)69:6<1373::AID-CNCR2820690612>3.0.CO;2-1","article-title":"Interleukin-6 dependence of advanced malignant plasma cell dyscrasias","volume":"69","author":"Zhang","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.103000_bib0022","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2008-07-170464","article-title":"The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor","volume":"113","author":"Sprynski","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.103000_bib0023","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/leu.2010.192","article-title":"Insulin is a potent myeloma cell growth factor through insulin\/IGF-1 hybrid receptor activation","volume":"24","author":"Sprynski","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.103000_bib0024","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood-2003-05-1510","article-title":"An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis","volume":"103","author":"Mahtouk","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.103000_bib0025","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.103000_bib0026","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood.V88.10.3998.bloodjournal88103998","article-title":"Hepatocyte growth factor and its receptor c-met in multiple myeloma","volume":"88","author":"Borset","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.103000_bib0027","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3324\/haematol.2010.033456","article-title":"A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines","volume":"96","author":"Moreaux","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2026.103000_bib0028","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.7150\/thno.54453","article-title":"Comprehensive characterization of the epigenetic landscape in Multiple Myeloma","volume":"12","author":"Alaterre","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.tranon.2026.103000_bib0029","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7150\/thno.28374","article-title":"Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance","volume":"9","author":"Vikova","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.tranon.2026.103000_bib0030","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/leu.2017.54","article-title":"RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma","volume":"31","author":"Viziteu","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.103000_bib0031","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/leu.2012.36","article-title":"Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins","volume":"26","author":"Schoenhals","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.103000_bib0032","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41375-021-01234-0","article-title":"RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators","volume":"35","author":"Kassambara","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.103000_bib0033","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","article-title":"On the exact distribution of maximally selected rank statistics","volume":"43","author":"Hothorn","year":"2003","journal-title":"Comput. Stat. Data Anal."},{"key":"10.1016\/j.tranon.2026.103000_bib0034","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.3390\/cancers13153755","article-title":"Transcription\/replication conflicts in tumorigenesis and their potential role as novel therapeutic targets in multiple myeloma","volume":"13","author":"Dutrieux","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.103000_bib0035","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.7150\/thno.101821","article-title":"Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction","volume":"15","author":"Ovejero","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.tranon.2026.103000_bib0036","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cyto.b.20517","article-title":"Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology","volume":"78B","author":"Cannizzo","year":"2010","journal-title":"Cytom. B Clin. Cytom."},{"key":"10.1016\/j.tranon.2026.103000_bib0037","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023023237","article-title":"Integrative single-cell chromatin and transcriptome analysis of human plasma cell differentiation","volume":"144","author":"Alaterre","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.103000_bib0038","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/sj.bjc.6601613","article-title":"Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model","volume":"90","author":"Menu","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2026.103000_bib0039","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International myeloma society\/international myeloma working group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103000_bib0040","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.2025029987","article-title":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling","volume":"146","author":"Beer","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.103000_bib0041","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2532226","article-title":"CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies","volume":"14","author":"Chemlal","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tranon.2026.103000_bib0042","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.leukres.2009.11.018","article-title":"Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma","volume":"34","author":"Ismail","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.tranon.2026.103000_bib0043","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/sj.leu.2403997","article-title":"IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma","volume":"20","author":"Chng","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.103000_bib0044","first-page":"16","article-title":"Functional investigation of IGF1R mutations in multiple myeloma","author":"Heredia-Guerrero","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.103000_bib0045","doi-asserted-by":"crossref","first-page":"48732","DOI":"10.18632\/oncotarget.8982","article-title":"The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential","volume":"7","author":"Bieghs","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2026.103000_bib0046","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13813450902736583","article-title":"The role of the insulin-like growth factor 1 receptor axis in multiple myeloma","volume":"115","author":"Menu","year":"2009","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.tranon.2026.103000_bib0047","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s12032-013-0805-3","article-title":"Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer","volume":"31","author":"Singh","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.tranon.2026.103000_bib0048","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1021\/jm9002395","article-title":"Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach","volume":"52","author":"Li","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tranon.2026.103000_bib0049","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fendo.2014.00224","article-title":"IGF-IR targeted therapy: past, present and future","volume":"5","author":"Janssen","year":"2014","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.tranon.2026.103000_bib0050","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0031","article-title":"Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer","volume":"30","author":"Galifi","year":"2023","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tranon.2026.103000_bib0051","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41419-020-2640-8","article-title":"Oncogene PRR14 promotes breast cancer through activation of PI3K signal pathway and inhibition of CHEK2 pathway","volume":"11","author":"Ren","year":"2020","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.tranon.2026.103000_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114394","article-title":"Monocytes from patients with myelodysplastic syndrome inhibit natural killer cell-mediated antitumor function through the CD200\/CD200R pathway","volume":"152","author":"Guo","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.tranon.2026.103000_bib0053","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s40425-019-0710-1","article-title":"Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200","volume":"7","author":"Mahadevan","year":"2019","journal-title":"J. ImmunOther Canc."},{"key":"10.1016\/j.tranon.2026.103000_bib0054","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.str.2013.03.008","article-title":"Structures of CD200\/CD200 receptor family and implications for topology, regulation, and evolution","volume":"21","author":"Hatherley","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.tranon.2026.103000_bib0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.taap.2012.01.007","article-title":"Lipid raft: a floating island of death or survival","volume":"259","author":"George","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tranon.2026.103000_bib0056","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/5584_2022_759","article-title":"Rafting on the plasma membrane: lipid rafts in signaling and disease","volume":"1436","author":"Isik","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.tranon.2026.103000_bib0057","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13167","article-title":"Lipid raft involvement in signal transduction in cancer cell survival, cell death and metastasis","volume":"55","author":"Li","year":"2022","journal-title":"Cell Proliferat."},{"key":"10.1016\/j.tranon.2026.103000_bib0058","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrc3277","article-title":"Spatial regulation of receptor tyrosine kinases in development and cancer","volume":"12","author":"Casaletto","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tranon.2026.103000_bib0059","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12943-024-02140-6","article-title":"Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation","volume":"23","author":"Guo","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2026.103000_bib0060","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41587-020-0481-8","article-title":"IGF-1R drugs travel from cancer cradle to Graves'","volume":"38","author":"Dolgin","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tranon.2026.103000_bib0061","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1200\/JCO.2007.15.9319","article-title":"Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma","volume":"26","author":"Lacy","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103000_bib0062","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41375-025-02522-9","article-title":"Targeting ABCD1-ACOX1-MET\/IGF1R axis suppresses multiple myeloma","volume":"39","author":"Han","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.103000_bib0063","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2018.208306","article-title":"Kinome expression profiling to target new therapeutic avenues in multiple myeloma","volume":"105","author":"de Boussac","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2026.103000_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1271847","article-title":"Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma","volume":"13","author":"Bruyer","year":"2023","journal-title":"Front. Oncol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:43:03Z","timestamp":1790739783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326003360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":64,"alternative-id":["S1936523326003360"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103000","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103000"}}